CODX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CODX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Co-Diagnostics's average Accounts Receivable for the three months ended in Dec. 2023 was $0.56 Mil. Co-Diagnostics's Revenue for the three months ended in Dec. 2023 was $3.56 Mil. Hence, Co-Diagnostics's Days Sales Outstanding for the three months ended in Dec. 2023 was 14.26.
The historical rank and industry rank for Co-Diagnostics's Days Sales Outstanding or its related term are showing as below:
During the past 9 years, Co-Diagnostics's highest Days Sales Outstanding was 136.88. The lowest was 30.03. And the median was 109.66.
Co-Diagnostics's Days Sales Outstanding declined from Dec. 2022 (371.77) to Dec. 2023 (14.26).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
The historical data trend for Co-Diagnostics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 122.23 | 30.03 | 61.48 | 129.57 | 100.68 |
Co-Diagnostics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 371.77 | 466.56 | 875.40 | 35.36 | 14.26 |
For the Medical Devices subindustry, Co-Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Co-Diagnostics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (3.454 | + | 0.304) | / | 2 ) | / | 6.812 | * | 365 |
= | 1.879 | / | 6.812 | * | 365 | ||||
= | 100.68 |
Co-Diagnostics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding (Q: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Sep. 2023 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (0.807 | + | 0.304) | / | 2 ) | / | 3.555 | * | 365 / 4 |
= | 0.5555 | / | 3.555 | * | 365 / 4 | ||||
= | 14.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (NAS:CODX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Co-Diagnostics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Lee Brown | officer: Chief Financial Officer | 5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096 |
Ted Murphy | director | 64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1 |
Eugene Durenard | director | 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109 |
Dwight H Egan | director, officer: CEO and President | 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124 |
Richard S Serbin | director | 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022 |
James B Nelson | director | 26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010 |
Reed L Benson | officer: CFO and Secretary | 7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047 |
Edward L. Murphy | director | 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109 |
Brent Satterfield | director, officer: Chief Science Officer | 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124 |
America 2030 Capital, Llc | 10 percent owner | 1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144 |
Edward Borkowski | director | 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317 |
Frank J Kiesner | director | 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124 |
Reagents, Llc | 10 percent owner | 8160 S. HIGHLAND DR, SANDY UT 84093 |
Legends Capital Group, Llc | 10 percent owner | 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124 |
From GuruFocus
By PRNewswire • 11-29-2023
By PRNewswire PRNewswire • 02-22-2023
By PRNewswire • 12-27-2023
By PRNewswire • 08-10-2023
By PRNewswire • 08-29-2023
By PRNewswire • 10-31-2023
By PRNewswire PRNewswire • 03-17-2023
By PRNewswire • 08-18-2023
By PRNewswire • 09-21-2023
By PRNewswire • 07-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.